Physician profile
Henry Mroch
NPI 1245324219
$1,224.06
in general payments reported to CMS, 2019-2025
20 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $34.94 · 2021: $27.28 · 2022: $20.33 · 2023: $245 · 2024: $327 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $282.17 | 2023-2025 | Tavneos, Krystexxa, Parsabiv |
| Vifor Pharma, INC. | $169.65 | 2019-2025 | Veltassa |
| Novo Nordisk INC | $158.12 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $122.97 | 2024-2025 | |
| Glaxosmithkline, LLC. | $74.37 | 2023-2025 | Benlysta, Jesduvroq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.60 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $52.28 | 2025 | Tarpeyo |
| Ardelyx, INC. | $37.90 | 2024-2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $34.58 | 2025 | Oxlumo |
| Scpharmaceuticals INC. | $24.86 | 2025 | |
| Ucb, INC. | $23.00 | 2024 | Cimzia |
| Janssen Biotech, INC. | $22.43 | 2024 | Tremfya |
| Fresenius Kabi USA, LLC | $21.04 | 2024 | Idacio |
| Lilly USA, LLC | $20.84 | 2024 | Mounjaro, Zepbound |
| Horizon Therapeutics Plc | $20.33 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20.09 | 2024 | Farxiga |
| Fresenius USA Marketing, INC. | $19.05 | 2019 | |
| Recordati_rare_diseases_inc. | $17.70 | 2023 | Isturisa, Signifor Lar |
| Janssen Pharmaceuticals, INC | $16.37 | 2020 | |
| Amryt Pharma Holdings LTD | $13.71 | 2023 | Mycapssa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Mroch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.